SATURDAY, OCTOBER 1, 2016

NanoBio Corporation has positive pre-clinical trial for RSV vaccine

NanoBio Corporation announced on Tuesday that it will be presenting data from a positive pre-clinical trial for its intramuscular respiratory syncytial virus vaccine at the National Foundation for Infectious Diseases.

Research for the intramuscular nanoemulsion-adjuvanted RSV vaccine was derived using the company's NanoStat Technology and was proven in a pre-clinical study with cotton rats to protect the animals from RSV, without causing the disease to progress. NanoBio will present "A Novel Intramuscular W805EC Nanoemulsion Adjuvanted Respiratory Syncytial Virus Vaccine Protects Cotton Rats against RSV Challenge" on Wednesday at NFID 2013 in Baltimore."

"RSV is a significant cause of respiratory illness in young children and elderly persons, but to date, no commercially available vaccine exists," NanoBio's Senior Vice President of Vaccine Research Ali Fattom said. "While data supporting the use of the NanoStat technology as an intranasal adjuvant has been previously reported for several vaccines, recent studies, including those being presented this week at NFID, demonstrate the potential benefit of the technology as an intramuscular adjuvant. Because an RSV vaccine would mark a major step forward in the prevention of pediatric hospitalizations, future clinical development of the NanoStat IM adjuvant in RSV and other diseases is being planned."

Key highlights that will be part of NanoBio's presentation are that the vaccine was safe and highly immunogenic, generated high-quality antibodies, created a balanced Th1/Th2 autoimmune response and protected the cotton rats from the virus without histopathology.

RSV is the number one cause of hospitalizations of children and causes bronchiolitis and pneumonia. Almost every child is infected with the virus by early childhood and it can cause asthma if the infection persists throughout adulthood. The disease is also dangerous to the elderly.